MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

Search

Omeros Corp

Fechado

SetorSaúde

4.39 -0.9

Visão Geral

Variação de preço das ações

24h

Atual

Mín

4.35

Máximo

4.52

Indicadores-chave

By Trading Economics

Rendimento

8M

-25M

Margem de lucro

-8,121.359

Funcionários

202

EBITDA

9.3M

-26M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+72.07% upside

Dividendos

By Dow Jones

Próximos Ganhos

12 de nov. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

36M

314M

Abertura anterior

5.29

Fecho anterior

4.39

Sentimento de Notícias

By Acuity

13%

87%

13 / 371 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

Omeros Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

7 de out. de 2025, 16:58 UTC

Ganhos

BMW Trims 2025 View, Citing Weaker Performance in China

7 de out. de 2025, 23:43 UTC

Conversa de Mercado

Nikkei May Trade Rangebound; Takaichi's Policy Steps in Focus -- Market Talk

7 de out. de 2025, 23:36 UTC

Conversa de Mercado

Gold Edges Higher, Supported by Possible Hedging Demand -- Market Talk

7 de out. de 2025, 23:19 UTC

Conversa de Mercado

Veem Can Secure More Defense Deals Following Northrop Grumman Win -- Market Talk

7 de out. de 2025, 22:50 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

7 de out. de 2025, 22:50 UTC

Conversa de Mercado

RBNZ Should Take the Option of a Bigger Cut -- Market Talk

7 de out. de 2025, 22:40 UTC

Conversa de Mercado

South32's Alaskan Project Seen Starting Sooner, Worth More After U.S. Deal -- Market Talk

7 de out. de 2025, 21:56 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

7 de out. de 2025, 21:56 UTC

Conversa de Mercado

Australia Shares Set to Start Day Roughly Flat -- Market Talk

7 de out. de 2025, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

7 de out. de 2025, 20:44 UTC

Ações em Alta

Stocks to Watch Tuesday Recap: Oracle, Dell, Trilogy Metals -- WSJ

7 de out. de 2025, 19:42 UTC

Conversa de Mercado

Treasury Yields Fall as Data Blackout Continues -- Market Talk

7 de out. de 2025, 19:23 UTC

Aquisições, Fusões, Aquisições de Empresas

Private-Equity Stocks Have Gotten Crushed. J.P. Morgan Says This One Is a Buy. -- Barrons.com

7 de out. de 2025, 19:07 UTC

Conversa de Mercado

Oil Futures Settle Mixed With Higher OPEC+ Supply in View -- Market Talk

7 de out. de 2025, 19:02 UTC

Conversa de Mercado

U.S. Natural Gas Posts Back-to-Back Gains -- Market Talk

7 de out. de 2025, 16:20 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

7 de out. de 2025, 16:20 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

7 de out. de 2025, 16:20 UTC

Conversa de Mercado

Home Depot Extended Pro Desk Hours Could Drive Sales Growth -- Market Talk

7 de out. de 2025, 16:15 UTC

Conversa de Mercado

AMD's OpenAI Deal Resets Competitive Landscape for Chips -- Market Talk

7 de out. de 2025, 16:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

7 de out. de 2025, 15:37 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

7 de out. de 2025, 15:37 UTC

Conversa de Mercado

Markets for Canadian Aluminum Open Up Beyond U.S. -- Market Talk

7 de out. de 2025, 15:33 UTC

Conversa de Mercado

Gold Rise Tied to Lower Confidence in Dollar Assets -- Market Talk

7 de out. de 2025, 15:25 UTC

Conversa de Mercado

Canadian Mining Stocks Rally on U.S. Defense Dept. Deal -- Market Talk

7 de out. de 2025, 15:15 UTC

Conversa de Mercado

Investors Look to Gold, Bitcoin as Traditional Correlations Break Down -- Market Talk

7 de out. de 2025, 15:04 UTC

Conversa de Mercado

Market Talk Roundup: Latest on U.S. Politics

7 de out. de 2025, 15:04 UTC

Conversa de Mercado

Canadian Aluminum Exports Squeezed by Tariffs -- Market Talk

7 de out. de 2025, 14:56 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

7 de out. de 2025, 14:56 UTC

Conversa de Mercado

U.S. Government Shutdown May Impact Release of Canadian Trade Data -- Market Talk

7 de out. de 2025, 14:52 UTC

Ganhos

These Stocks Are Moving the Most Today: Tesla, AMD, Ford, Dell, IBM, AppLovin, Trilogy Metals, Aehr, and More -- Barrons.com

Comparação entre Pares

Variação de preço

Omeros Corp Previsão

Preço-alvo

By TipRanks

72.07% parte superior

Previsão para 12 meses

Média 7.64 USD  72.07%

Máximo 9 USD

Mínimo 6.277 USD

Com base em 3 analistas de Wall Street que oferecem metas de preço de 12 meses para Omeros Corp - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

3 ratings

2

Comprar

1

Manter

0

Vender

Pontuação Técnica

By Trading Central

6.265 / 7.49Suporte e Resistência

Curto Prazo

Very Strong Bearish Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

Weak Bullish Evidence

Sentimento

By Acuity

13 / 371 Ranking em Saúde

Sentimento de Notícias

Evidência Muito Forte de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Omeros Corp

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
help-icon Live chat